EUCTR2012-002464-27-IT招募中1 期
onmyeloablative Hematopoietic Stem Cell Transplantation for Patients with solid tumors metastatic or relapsed, resistant/refractory to conventional therapy, using HLA-identical related donors or HLA-Haploidentical related donors - ND
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •-Histologically or cytologically proven diagnosis of renal cell cancer, neurendocrine cancer, pancreatic cancer, rhinopharyngeal lymphoepithelioma, malignant melanoma, soft-tissue sarcoma, ovarian carcinoma, gastric carcinoma, germ cell tumors, breast cancer, colorectal cancer with evidence of unresectable, locally recurrent, or metastatic disease. Locally recurrent disease must not be amenable to resection or radiation therapy with curative intent
- •-Recurrent/refractory disease after primary treatment and deemed not suitable for standard therapy. Metastatic disease not eligible for standard therapy-potentially curative or able to extend life expectancy.
- •-Prior treatment with chemotherapy as follows: receipt of adjuvant chemotherapy with RECIST defined disease progression documented during treatment or disease relapse within 6 months of last treatment, or receipt of chemotherapy in the first-line advanced disease setting with RECIST defined disease stable or progression documented during treatment, or, if the patient completed treatment with objective disease response, documented disease stable or progression after discontinuing treatment. Patients entering the study on the basis of this criterion may have also previously received neoadjuvant or adjuvant treatment with chemotherapy.
- •-Measurable disease as per RECIST. Measurable lesions that have been previously radiated will not be considered target lesions unless increase in size has been observed following completion of radiation therapy.
- •-Male or female.
- •-Patients age > 18 and < 70 years.
- •-ECOG performance status 0-2.
- •-Resolution of all acute toxic effects of prior therapy or surgical procedures to grade =1 (except alopecia).
- •-Life expectancy >3 months.
- •-A fully HLA-identical or alternatively an HLA haploidentical related donor is available.
- •-The definitions of minimum adequacy for organ function required prior to study entry are as follows:
- •. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) =2.5 x upper limit of normal (ULN), or AST and ALT =5 x ULN if liver function abnormalities are due to underlying malignancy
- •. Total serum bilirubin =1.5 x ULN
- •. Absolute neutrophil count (ANC) =1500/µL
- •. Platelets =100,000/µL
- •. Haemoglobin =9.0 g/dL
- •. Serum creatinine =1.5 x ULN
- •-Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrolment.
- •-Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 16
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •-Uncontrolled CNS involvement with disease
- •-Fertile men or women unwilling to use contraceptive techniques during and for 12 months following treatment
- •-Females who are pregnant
- •-Organ dysfunction defined as follows:
- •¿Cardiac ejection fraction <30% or uncontrolled cardiac failure
- •¿Pulmonary: DLCO <40% predicted
- •¿Liver: elevation of bilirubin to > 1.5 x ULN and/or transaminases >5x the upper limit of normal
- •¿Renal: Serum creatinine >1.5 x ULN
- •-ECOG performance status >2
- •-Patients with poorly controlled hypertension on multiple antihypertensives
- •-Documented fungal disease that is progressive despite treatment
- •-Viral infections: HIV positive patients. Hepatitis B and C positive patients will be evaluated on a case by case basis
- •-Psychiatric disorders or psychosocial problems which in the opinion of the primary physician or Principal Investigator would place the patient at unacceptable risk from this regimen.
- •-Patients may not be receiving any other investigational agents.
- •-History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in the study.
- •-Any previous or current malignancy at other sites, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix and adequately treated basal or squamous cell carcinoma of the skin.
研究者
相似试验
进行中（未招募）
不适用
onmyeloablative Hematopoietic Stem Cell Transplantation for Patients with High-Risk Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression with cyclophosfamide administered Before and After Transplantation. A monocentric study. - NDHigh risk Hematologic MalignanciesMedDRA version: 9.1Level: HLGTClassification code 10024324MedDRA version: 9.1Level: HLGTClassification code 10025323EUCTR2009-018083-94-ITISTITUTO EUROPEO DI ONCOLOGIA
已完成
2 期
Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1HIRCT138706061030N2Tehran University of Medical Sciences10
进行中（未招募）
1 期
Stem cells transplant from matched donor in patients with chronic myeloid leukemia who do not improve with TKI therapyChronic Myeloid LeukemiaMedDRA version: 18.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864EUCTR2014-003126-40-ITIVERSITà DEGLI STUDI MILANO BICOCCA20
已完成
不适用
Allogeneic hematopoietic stem cell transplantation for elderly patientsJPRN-UMIN000017744nivesity of Tokyo Hospital, Department of Hematology and Oncology50
已完成
不适用
Allogeneic hematopoietic stem cell transplantation (HSCT) from HLA-haploidentical related donor using reduced dose of posttransplantation high-dose cyclophosphamide (PTCy) for poor prognosis or refractory hematological malignancies (OCU16-2)Acute myeloid leukemia(AML) Acute lymphoblastic leukemia(ALL) Acute leukemias of ambiguous lineage Myelodysplastic syndrome(MDS) Chronic myeloid leukemia(CML) Adult T-cell leukemia/lymphoma(ATLL) Malignant lymphoma(ML)JPRN-UMIN000026028Osaka City University33